Key facts
- This page summarizes Sheila Gujrathi's Form 3 filing for BlossomHill Therapeutics, Inc. (BLSM).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 06 Aug 2026, 20:47.
Sheila Gujrathi - 06 Aug 2026 Form 3 Insider Report for BlossomHill Therapeutics, Inc. (BLSM)
- Reporting relationship
- Director
- Issuer ticker
- BLSM
- Reported as of
- 06 Aug 2026
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 06 Aug 2026, 20:47:05 UTC
- Prior SEC filing
- 30 Jul 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Vincent Liptak, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sheila Gujrathi filed Form 3 for BlossomHill Therapeutics, Inc. (BLSM) on 06 Aug 2026.
Change
- Previous filing in this sequence was filed on 30 Jul 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001575202
Primary reporting owner
GUJRATHI SHEILA
- Relationship
- Director
- Address
- C/O BLOSSOMHILL THERAPEUTICS, INC., 10255 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO
- Signature
- /s/ Vincent Liptak, Attorney-in-Fact
- Signature date
- 06 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BLSM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 90,160
- Date
- 06 Aug 2026
- Ownership
- Direct
* marks a reported price that did not pass the local price check.